glofitamab,Obinutuzumab 
roche
['glofitamab', 'dlbcl', 'car-t', 'pivotal']
#asco22 #pivotaltrial of glofitamab in r/r #dlbcl: 154 pts; median of 3 prior lines; 33% prior car-t cr rate 39.4% cr rate in pts relapsed vs refractory to last tx (70% vs 34%) 12-mo efs 37%; 12-mo os 50% crs 63% (3.9% g3/4); mostly during c1 
CME experts Sara Fagerlie, PhD, CHCP and Mindy Tanzola, PhD founded Front Row CME to help clinicians and educators manage the oncology information deluge.